Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19916991,CL/F,"The final population parameter estimates (95% CI) were: CL/F, 10.4 l h(-1) (10.2, 10.6); V(2)/F, 337 l (309, 364); V(3)/F, 78.1 l (61.9, 98.9); Q/F, 2.08 l h(-1) (1.39, 3.79); K(a), 1.69 h(-1) (1.27, 2.00); and A(lag), 0.43 h (0.37, 0.46).",Population pharmacokinetic analysis of varenicline in adult smokers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916991/),[l] / [h],10.4,13255,DB01273,Varenicline
,19916991,V(2)/F,"The final population parameter estimates (95% CI) were: CL/F, 10.4 l h(-1) (10.2, 10.6); V(2)/F, 337 l (309, 364); V(3)/F, 78.1 l (61.9, 98.9); Q/F, 2.08 l h(-1) (1.39, 3.79); K(a), 1.69 h(-1) (1.27, 2.00); and A(lag), 0.43 h (0.37, 0.46).",Population pharmacokinetic analysis of varenicline in adult smokers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916991/),l,337,13256,DB01273,Varenicline
,19916991,V(3)/F,"The final population parameter estimates (95% CI) were: CL/F, 10.4 l h(-1) (10.2, 10.6); V(2)/F, 337 l (309, 364); V(3)/F, 78.1 l (61.9, 98.9); Q/F, 2.08 l h(-1) (1.39, 3.79); K(a), 1.69 h(-1) (1.27, 2.00); and A(lag), 0.43 h (0.37, 0.46).",Population pharmacokinetic analysis of varenicline in adult smokers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916991/),l,78.1,13257,DB01273,Varenicline
,19916991,Q/F,"The final population parameter estimates (95% CI) were: CL/F, 10.4 l h(-1) (10.2, 10.6); V(2)/F, 337 l (309, 364); V(3)/F, 78.1 l (61.9, 98.9); Q/F, 2.08 l h(-1) (1.39, 3.79); K(a), 1.69 h(-1) (1.27, 2.00); and A(lag), 0.43 h (0.37, 0.46).",Population pharmacokinetic analysis of varenicline in adult smokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916991/),[l] / [h],2.08,13258,DB01273,Varenicline
,19916991,K(a),"The final population parameter estimates (95% CI) were: CL/F, 10.4 l h(-1) (10.2, 10.6); V(2)/F, 337 l (309, 364); V(3)/F, 78.1 l (61.9, 98.9); Q/F, 2.08 l h(-1) (1.39, 3.79); K(a), 1.69 h(-1) (1.27, 2.00); and A(lag), 0.43 h (0.37, 0.46).",Population pharmacokinetic analysis of varenicline in adult smokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916991/),1/[h],1.69,13259,DB01273,Varenicline
,19916991,A(lag),"The final population parameter estimates (95% CI) were: CL/F, 10.4 l h(-1) (10.2, 10.6); V(2)/F, 337 l (309, 364); V(3)/F, 78.1 l (61.9, 98.9); Q/F, 2.08 l h(-1) (1.39, 3.79); K(a), 1.69 h(-1) (1.27, 2.00); and A(lag), 0.43 h (0.37, 0.46).",Population pharmacokinetic analysis of varenicline in adult smokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916991/),h,0.43,13260,DB01273,Varenicline
,19916991,CL/F,"CL/F decreased from 10.4 l h(-1) for a typical subject with normal renal function (CLcr = 100 ml min(-1)) to 4.4 l h(-1) for a typical subject with severe renal impairment (CLcr = 20 ml min(-1)), which corresponds to a 2.4-fold increase in daily steady-state exposure.",Population pharmacokinetic analysis of varenicline in adult smokers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916991/),[l] / [h],10.4,13261,DB01273,Varenicline
,19916991,CL/F,"CL/F decreased from 10.4 l h(-1) for a typical subject with normal renal function (CLcr = 100 ml min(-1)) to 4.4 l h(-1) for a typical subject with severe renal impairment (CLcr = 20 ml min(-1)), which corresponds to a 2.4-fold increase in daily steady-state exposure.",Population pharmacokinetic analysis of varenicline in adult smokers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916991/),[l] / [h],4.4,13262,DB01273,Varenicline
,20551220,half-life,Mean half-life estimates ranged from approximately 13 to 19 hours after single dosing and 24 to 28 hours after repeat dosing.,"Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551220/),h,13 to 19,24054,DB01273,Varenicline
,20551220,half-life,Mean half-life estimates ranged from approximately 13 to 19 hours after single dosing and 24 to 28 hours after repeat dosing.,"Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551220/),h,24 to 28,24055,DB01273,Varenicline
,30349192,specific surface area,"VRC-S showed a positively skewed unimodal size distribution with a specific surface area of 2.02 m2/g, single endothermic peak of 225.2°C in differential scanning calorimetry, crystalline internal structure in powder X-ray diffraction, aqueous solubility of 244.7 mg/mL, and hygroscopicity of 0.256 mg/g.",Immediate release tablet formulation of varenicline salicylate and comparative pharmacokinetic study in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349192/),[m2] / [g],2.02,32466,DB01273,Varenicline
,30349192,solubility,"VRC-S showed a positively skewed unimodal size distribution with a specific surface area of 2.02 m2/g, single endothermic peak of 225.2°C in differential scanning calorimetry, crystalline internal structure in powder X-ray diffraction, aqueous solubility of 244.7 mg/mL, and hygroscopicity of 0.256 mg/g.",Immediate release tablet formulation of varenicline salicylate and comparative pharmacokinetic study in human volunteers. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349192/),[mg] / [ml],244.7,32467,DB01273,Varenicline
,30349192,f 2,"The dissolution of VRC was pH independent, revealing f 2 values of 76.49 and 68.38 at pH 1.2 and pH 6.8, respectively.",Immediate release tablet formulation of varenicline salicylate and comparative pharmacokinetic study in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349192/),,76.49,32468,DB01273,Varenicline
,30349192,f 2,"The dissolution of VRC was pH independent, revealing f 2 values of 76.49 and 68.38 at pH 1.2 and pH 6.8, respectively.",Immediate release tablet formulation of varenicline salicylate and comparative pharmacokinetic study in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349192/),,68.38,32469,DB01273,Varenicline
,33704052,maximum plasma varenicline concentration (Cmax),"The maximum plasma varenicline concentration (Cmax) was 5,768.95 ng/L (mean) and 5,780.55 ng/L for the test drug and reference drug, respectively.",Pharmacokinetic comparison between tablet of varenicline tartrate and orally disintegrating film of varenicline salicylate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33704052/),[ng] / [l],"5,768.95",43310,DB01273,Varenicline
,33704052,maximum plasma varenicline concentration (Cmax),"The maximum plasma varenicline concentration (Cmax) was 5,768.95 ng/L (mean) and 5,780.55 ng/L for the test drug and reference drug, respectively.",Pharmacokinetic comparison between tablet of varenicline tartrate and orally disintegrating film of varenicline salicylate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33704052/),[ng] / [l],"5,780.55",43311,DB01273,Varenicline
,33704052,areas under the concentration-time curve from time 0 to the last measurable time point (AUC0-t),"The areas under the concentration-time curve from time 0 to the last measurable time point (AUC0-t) were 94,086.30 h×ng/L and 89,958.55 h×ng/L for the test drug and reference drug, respectively.",Pharmacokinetic comparison between tablet of varenicline tartrate and orally disintegrating film of varenicline salicylate in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33704052/),[h·ng] / [l],"94,086.30",43312,DB01273,Varenicline
,33704052,areas under the concentration-time curve from time 0 to the last measurable time point (AUC0-t),"The areas under the concentration-time curve from time 0 to the last measurable time point (AUC0-t) were 94,086.30 h×ng/L and 89,958.55 h×ng/L for the test drug and reference drug, respectively.",Pharmacokinetic comparison between tablet of varenicline tartrate and orally disintegrating film of varenicline salicylate in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33704052/),[h·ng] / [l],"89,958.55",43313,DB01273,Varenicline
,30868192,CL/F,"CL/F was 8.5 L/h (coefficient of variation, 26%), V/F was 228 L, and the absorption rate (ka) was fixed to 0.98 h-1.",Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30868192/),[l] / [h],8.5,47039,DB01273,Varenicline
,30868192,V/F,"CL/F was 8.5 L/h (coefficient of variation, 26%), V/F was 228 L, and the absorption rate (ka) was fixed to 0.98 h-1.",Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30868192/),l,228,47040,DB01273,Varenicline
,30868192,absorption rate (ka),"CL/F was 8.5 L/h (coefficient of variation, 26%), V/F was 228 L, and the absorption rate (ka) was fixed to 0.98 h-1.",Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30868192/),1/[h],0.98,47041,DB01273,Varenicline
,31699211,Cmax,"The observed average values of Cmax, AUClast, and AUCinf were 4.46 ng/mL, 97.68 ng×h/mL, and 101.60 ng×h/mL for reference and 4.54 ng/mL, 97.10 ng×h/mL, and 100.97 ng×h/mL for test, respectively.",Pharmacokinetic comparisons of two different varenicline formulations in humans: Varenicline tartrate versus varenicline oxalate . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31699211/),[ng] / [ml],4.46,76833,DB01273,Varenicline
,31699211,AUClast,"The observed average values of Cmax, AUClast, and AUCinf were 4.46 ng/mL, 97.68 ng×h/mL, and 101.60 ng×h/mL for reference and 4.54 ng/mL, 97.10 ng×h/mL, and 100.97 ng×h/mL for test, respectively.",Pharmacokinetic comparisons of two different varenicline formulations in humans: Varenicline tartrate versus varenicline oxalate . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31699211/),[h·ng] / [ml],97.68,76834,DB01273,Varenicline
,31699211,AUClast,"The observed average values of Cmax, AUClast, and AUCinf were 4.46 ng/mL, 97.68 ng×h/mL, and 101.60 ng×h/mL for reference and 4.54 ng/mL, 97.10 ng×h/mL, and 100.97 ng×h/mL for test, respectively.",Pharmacokinetic comparisons of two different varenicline formulations in humans: Varenicline tartrate versus varenicline oxalate . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31699211/),[h·ng] / [ml],97.10,76835,DB01273,Varenicline
,31699211,AUCinf,"The observed average values of Cmax, AUClast, and AUCinf were 4.46 ng/mL, 97.68 ng×h/mL, and 101.60 ng×h/mL for reference and 4.54 ng/mL, 97.10 ng×h/mL, and 100.97 ng×h/mL for test, respectively.",Pharmacokinetic comparisons of two different varenicline formulations in humans: Varenicline tartrate versus varenicline oxalate . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31699211/),[h·ng] / [ml],101.60,76836,DB01273,Varenicline
,31699211,AUCinf,"The observed average values of Cmax, AUClast, and AUCinf were 4.46 ng/mL, 97.68 ng×h/mL, and 101.60 ng×h/mL for reference and 4.54 ng/mL, 97.10 ng×h/mL, and 100.97 ng×h/mL for test, respectively.",Pharmacokinetic comparisons of two different varenicline formulations in humans: Varenicline tartrate versus varenicline oxalate . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31699211/),[h·ng] / [ml],100.97,76837,DB01273,Varenicline
,19243716,CL/F,"The CL/F for a 70-kg adolescent was 10.4 L/h, comparable to that in a 70-kg adult.","Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243716/),[l] / [h],10.4,82432,DB01273,Varenicline
,19243716,AUC(0-24),"In high-body-weight subjects, steady-state varenicline exposure, as represented by the AUC(0-24), was 197.0 ng . h/mL for varenicline 1 mg BID and 95.7 ng .","Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243716/),[h·ng] / [ml],197.0,82433,DB01273,Varenicline
,19243716,AUC(0-24),"In high-body-weight subjects, steady-state varenicline exposure, as represented by the AUC(0-24), was 197.0 ng . h/mL for varenicline 1 mg BID and 95.7 ng .","Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243716/),ng,95.7,82434,DB01273,Varenicline
,19243716,exposure,"In low-body-weight subjects, varenicline exposure was 126.3 ng . h/mL for varenicline 0.5 mg BID and 60.1 ng .","Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243716/),[h·ng] / [ml],126.3,82435,DB01273,Varenicline
,21053991,elimination half-life,"Consistent with an elimination half-life of ∼24 hours, steady-state conditions are reached within 4 days of repeat dosing.",A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053991/),h,∼24,138379,DB01273,Varenicline
,20466870,time to maximum concentration,Median time to maximum concentration was 3 hours.,"Pharmacokinetics, safety, and tolerability following multiple oral doses of varenicline under various titration schedules in elderly nonsmokers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20466870/),h,3,187033,DB01273,Varenicline
,20466870,elimination half-life,Mean elimination half-life was estimated to be approximately 24 to 32 hours and independent of dose.,"Pharmacokinetics, safety, and tolerability following multiple oral doses of varenicline under various titration schedules in elderly nonsmokers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20466870/),h,24 to 32,187034,DB01273,Varenicline
,19356390,tmax (time of occurrence of Cmax),"Median values of tmax (time of occurrence of Cmax) were similar for both dosing regimens (3.0 and 2.5 h following single and multiple dosing, respectively).",The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356390/),h,3.0,191809,DB01273,Varenicline
,19356390,tmax (time of occurrence of Cmax),"Median values of tmax (time of occurrence of Cmax) were similar for both dosing regimens (3.0 and 2.5 h following single and multiple dosing, respectively).",The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356390/),h,2.5,191810,DB01273,Varenicline
,19356390,elimination half-life,"The mean elimination half-life following single and multiple dosing was 15.2 and 18.3 h, respectively.",The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356390/),h,15.2,191811,DB01273,Varenicline
,19356390,elimination half-life,"The mean elimination half-life following single and multiple dosing was 15.2 and 18.3 h, respectively.",The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356390/),h,18.3,191812,DB01273,Varenicline
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],71.7,268712,DB01273,Varenicline
,27940077,t1/2,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),min,116,268713,DB01273,Varenicline
,27940077,clearance,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ml] / [kg·min],6.25,268714,DB01273,Varenicline
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],191,268715,DB01273,Varenicline
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],63,268716,DB01273,Varenicline
,27940077,ED50,The ED50 value of nicotine to produce discriminative stimulus effects was 0.013 mg/kg.,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.013,268717,DB01273,Varenicline
,27940077,ED50,"Epibatidine and varenicline increased drug-lever responding to 97% and 95%, respectively (ED50 values = 0.00015 and 0.031 mg/kg, respectively), whereas cocaine, midazolam, and morphine produced no more than 28% drug-appropriate responding.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.00015,268718,DB01273,Varenicline
,27940077,ED50,"Epibatidine and varenicline increased drug-lever responding to 97% and 95%, respectively (ED50 values = 0.00015 and 0.031 mg/kg, respectively), whereas cocaine, midazolam, and morphine produced no more than 28% drug-appropriate responding.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.031,268719,DB01273,Varenicline
,27940077,apparent pA2,DHβE (0.1 and 0.32) produced rightward shifts of the nicotine and varenicline dose-response functions; Schild plots fitted through individual data resulted in slopes that were not different from unity; the apparent pA2 calculated for DHβE did not significantly differ in the presence of nicotine (6.58) or varenicline (6.45).,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),,6.58,268720,DB01273,Varenicline
,27940077,apparent pA2,DHβE (0.1 and 0.32) produced rightward shifts of the nicotine and varenicline dose-response functions; Schild plots fitted through individual data resulted in slopes that were not different from unity; the apparent pA2 calculated for DHβE did not significantly differ in the presence of nicotine (6.58) or varenicline (6.45).,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),,6.45,268721,DB01273,Varenicline
